Tricyclo Ring System Having The Seven-membered Hetero Ring As One Of The Cyclos Patents (Class 514/220)
-
Publication number: 20110237537Abstract: Described herein are assays, kits and methods for treating mood disorders by testing for one or more polymorphisms in a specific group of genes and for analyzing the results of polymorphism testing; the genes included may converge in one or more signaling pathways, and may be epigenetic. The genes are included based on the relationships of the proteins encoded by the genes in the context of particular signaling pathways and provide a diagnostically relevant nexus. Also described herein are methods of presenting the data collected by the screen, including methods of delivering interpretive comments and/or treatment guidance based on the results of the genetic screening either individually or based on the genetic composition of particular clusters of genes which may be related to each other. Importantly, drugs which modulate these genetic disturbances are described for targeted therapeutic use based upon companion diagnostic method.Type: ApplicationFiled: March 29, 2011Publication date: September 29, 2011Inventor: Jay L. Lombard
-
Publication number: 20110237563Abstract: The present invention related to the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with critical buccal condition, leading to difficulties in swallowing oral medicine forms and thus difficulties in treating said illnesses. Particularly, the present invention discloses the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with dysphagia and/or odynophagia and/or aspiration risk. Another aspect of the present invention is the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for the treatment of dysphagia and/or odynophagia and/or aspiration risk.Type: ApplicationFiled: March 23, 2010Publication date: September 29, 2011Inventor: Dominique Costantini
-
Publication number: 20110230460Abstract: The invention relates to new thienotriazolodiazepine derivatives of the formula (1) wherein R1 is CH3, R2 is CH3 or —(CH2)n—R4 or —(CH2)n—O—R4 or —(CH2)n—S—R4 wherein n is 1, 2, 3 or 4 and R4 is CH3, CH2CH3 or CH2CH2OCH3, and R3 is hydrogen or —OCH2O— or —OCH2CH2O— connected to the ortho/meta position or meta/para position of the phenyl ring; or wherein R1 and R2 are hydrogen and R3 is —OCH2O— Or —OCH2CH2O— connected to the ortho/meta position or meta/para position of the phenyl ring; and pharmaceutically acceptable acid addition salts thereof. These compounds and pharmaceutical compositions containing them are useful in the treatment and prevention of atherosclerotic artery diseases, such as myocardial infarction and stroke, and of Alzheimer's disease.Type: ApplicationFiled: October 29, 2009Publication date: September 22, 2011Applicant: CircoMed LLCInventors: Herman Kempen, Daniel Bellus, Barbara Staehelin
-
Patent number: 8022065Abstract: The present invention provides kinase inhibitors of Formula I.Type: GrantFiled: December 12, 2008Date of Patent: September 20, 2011Assignee: Eli Lilly and CompanyInventors: Thomas Albert Engler, James Robert Henry, Sushant Malhotra, Jon Kevin Reel
-
Publication number: 20110224195Abstract: The present invention is directed to substituted six-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as obesity and diabetes, particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.Type: ApplicationFiled: August 18, 2008Publication date: September 15, 2011Inventors: Tesfaye Biftu, Danqing Feng, Ann E. Weber, Jason M. Cox, Xiaoxia Qian, Jinyou Xu
-
Publication number: 20110224278Abstract: Methods for treating a central nervous system (CNS) injury in a subject are provided. Aspects of the methods include administering to the subject an effective amount of gamma aminobutyric acid (GABA) receptor signaling inhibitor to treat the subject for the CNS injury. Also provided are compositions finding use in embodiments of the methods. Methods and compositions of the invention find use in the treatment of a variety of different CNS injuries, including but not limited to, treating a subject for CNS injury associated with the occurrence of stroke.Type: ApplicationFiled: June 3, 2010Publication date: September 15, 2011Inventors: Stanley T. Carmichael, Istvan Mody, Andrew Clarkson, Justine J. Overman, Ben Huang
-
Publication number: 20110217341Abstract: The present invention relates to a method for preparing microspheres and microspheres prepared thereby, more particularly to a method for preparing a polymeric microsphere, including preparing an emulsion including a polymer compound, a drug, a water-insoluble organic solvent and a dispersion solvent and adding to the prepared emulsion a base or an acid to remove the water-insoluble organic solvent from the emulsion, a polymeric microsphere prepared thereby, and a composition for drug delivery including the microsphere. According to the present invention, a drug-containing polymer microsphere may be prepared quickly and simply without the solvent evaporation or solvent extraction process, thereby reducing water consumption and minimizing wastewater generation.Type: ApplicationFiled: May 12, 2011Publication date: September 8, 2011Applicants: EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION, SK CHEMICALS CO., LTD.Inventor: Hong Kee SAH
-
Patent number: 8012958Abstract: The present invention relates to methods of and compositions for treating and relieving symptoms and disease associated with indications caused by a physiological drive to alleviate a sensation of anxiety. In one treatment method, methods of, and compositions for, modulating the expression of certain GABAA receptor subunits are used to treat anxiety-related disorders and depressive disorders associated with physiological tolerance to endogenous neurosteroids.Type: GrantFiled: April 7, 2006Date of Patent: September 6, 2011Assignee: Hythlam, Inc.Inventors: Sanjay Sabnani, Donald Wesson
-
Publication number: 20110212156Abstract: Disclosed are pharmaceutical compositions, particularly oral dosage forms, which comprise two or more enteric coating materials, either as a coating or as part of a matrix dosage form, and methods of making and using the same. The compositions are characterized by having a sustained release profile at lower pH and an accelerated dissolution profile at higher pH.Type: ApplicationFiled: January 10, 2011Publication date: September 1, 2011Inventors: Rong-Kun Chang, Niraj Shah
-
Publication number: 20110206782Abstract: The present invention relates to new piperidine modulators of dopamine receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: February 15, 2011Publication date: August 25, 2011Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Chengzhi Zhang
-
Publication number: 20110207688Abstract: The present invention relates to a method of treating an HIV-I infection with a compound according to formula I where R1, R2, R3, R4, R5, are as defined herein.Type: ApplicationFiled: February 20, 2010Publication date: August 25, 2011Inventors: James Patrick Dunn, Todd Richard Elworthy, Dimitrios Stefanidis, Zachary Kevin Sweeney
-
Publication number: 20110207721Abstract: The present invention provides kinase inhibitors of Formula I.Type: ApplicationFiled: May 4, 2011Publication date: August 25, 2011Applicant: ELI LILLY AND COMPANYInventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
-
Publication number: 20110201600Abstract: The present invention relates to chalcone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation there of. More particularly it relates to 7-Methoxy-8-{n[4-1-(2 or 4-substituted phenyl)-3-(4-hydroxy-3-methoxyphenyl)-2-propen-1-one]alkyl}-oxy}-(11aS)-1,2,3,11a-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one and 7-Methoxy-8-{n[-3-(4-hydroxy-3-methoxyphenyl)-1-(2,4-alkyl-3-quinolyl)-2-propen-1-one]alkyl}-oxy-(11aS)-1,2,3,11a-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one with aliphatic chain length variations useful as anticancer (antitumour) agent. The general structural formula of these chalcone linked pyrrolo[2,1-c][1,4]benzodiazepines hybrids is given below.Type: ApplicationFiled: October 31, 2008Publication date: August 18, 2011Inventors: Ahmed Kamal, Bandari Rajendra Prasad, Adla Malla Reddy
-
Patent number: 7998954Abstract: The invention provides a pyrimidodiazepinone derivative represented by the general formula (I) [wherein n represents 1 or 2, Z represents a hydrogen atom or the like, R1 and R2 may be the same or different, and each represents a hydrogen atom or the like, A represents a bond, (CH2)m (wherein m represents an integer of 1 to 4), optionally substituted phenylene, optionally substituted pyridinediyl, or C?O, R3 represents a hydrogen atom, optionally substituted lower alkyl, or the like, and R4 represents a hydrogen atom or the like], or a pharmaceutically acceptable salt thereof or the like.Type: GrantFiled: June 2, 2008Date of Patent: August 16, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Nobumasa Otsubo, Yukihito Tsukumo, Kenji Uchida, Kyoichiro Iida, Hitoshi Arai, Shuko Okazaki, Takamichi Imaizumi
-
Patent number: 7998950Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: July 24, 2009Date of Patent: August 16, 2011Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Azim Alan Celebi, Zhimin Du, Salman Y. Jabri, Haolun Jin, Choung U. Kim, Jiayao Li, Samuel E. Metobo, Michael R. Mish, Barton W. Phillips, Joseph H. Saugier, Zheng-Yu Yang, Catalin Sebastian Zonte
-
Publication number: 20110195095Abstract: Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine.Type: ApplicationFiled: February 9, 2011Publication date: August 11, 2011Inventors: Gary Liversidge, Scott Jenkins, Elaine Merisko Liversidge
-
Publication number: 20110195950Abstract: The invention relates to compound of the formula I in which R1 represents an optionally substituted aryl group or an optionally substituted heteroaryl group; R2 represents hydrogen or a substituent different from hydrogen; R3 represents an optionally substituted aryl group, cycloalkyl group, heteroaryl group, heterocyclyl group; X1 represents O, S, NR4, CR42; X2 represents O, S, NR4, CR42; X3 represents O, S, NR4, CR42; X4 represents O, S, NR4, CR42; R4 represents hydrogen or a substituent different from hydrogen; R5 represents hydrogen or alkyl; Y represents O or S; m represents 0, 1, 2 or 3; n represents 0, 1, 2 or 3 in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.Type: ApplicationFiled: August 12, 2008Publication date: August 11, 2011Inventors: Samuel Hintermann, Konstanze Hurth, Marina Tintelnot-Blomley
-
Publication number: 20110195952Abstract: Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.Type: ApplicationFiled: January 11, 2011Publication date: August 11, 2011Applicant: Theracos, Inc.Inventors: Brian Seed, Jordan Mechanic
-
Patent number: 7994160Abstract: Disclosed are pyridazine compounds of the formula I which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds: In formula I indicates a single bond or a double bond; X is O, S or N—R5; R1, R2 are independently selected from the group consisting of H, NH2, NH—C1-C6-alkyl, OH, ?O, (i.e.Type: GrantFiled: July 12, 2006Date of Patent: August 9, 2011Assignee: Abbott GmbH & Co. KGInventors: Sean C. Turner, Margaretha Bakker, Roland Grandel, Michael Vierling
-
Publication number: 20110190275Abstract: The present invention provides a compounds of general formula IXa-d, useful as potential antitumour agents and pharmaceutical composition comprising these compounds exhibits binding affinity with calf thymus (CT) DNA at a molar ratio of 1:5 in aqueous sodium phosphate buffer at pH of 7.00. The present invention further provides a process for the preparation of C2-Fluoro substituted piperazine linked pyrrolo[2,1c][1-4], benzodiazepine of formula (IX).Type: ApplicationFiled: October 31, 2008Publication date: August 4, 2011Inventors: Ahmed Kamal, Rajender, Metuku Kashireddy, Gorre Balakishan
-
Publication number: 20110178068Abstract: The invention provides a method of sustained delivery of a tertiary amine-containing parent drug comprising administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile quaternary ammonium salts of tertiary amine-containing parent drugs (or tertiary imine-containing parent drugs) that are derivatized through aldehyde-linked prodrug moieties that reduce the solubility of the prodrug compound at a reference pH as compared to the parent drug. The physical, chemical and solubility properties of these derivatives can be further modulated by the choice of counterion X?. In one embodiment, the present invention provides a prodrug compound of Formula I: where R1-R5 are defined in the written description of the invention.Type: ApplicationFiled: December 23, 2010Publication date: July 21, 2011Applicant: Alkermes, Inc.Inventors: Orn Almarsson, Laura Cook Blumberg, Julius F. Remenar
-
Patent number: 7981884Abstract: The invention relates to a process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno-[2,3-b][1,5]benzodiazepine (olanzapine) of the formula (I) by reacting 4-amino-2-methyl-10H-thieno[2,3-b][1/5]benzodiazepine hydrochloride of the formula (II) with N-methylpiperazine in an organic solvent, which comprises carrying out the reaction in the mixture of toluene and 1,3-dimethyl-2-imidazolidinone. The invention also encompasses new 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b] [1,5]benzodiazepine dihydrochloride trihydrate of the formula (IB), the preparation thereof and pharmaceutical compositions comprising said new compound.Type: GrantFiled: November 10, 2006Date of Patent: July 19, 2011Assignee: Egis Gyogyszergyar Nyilvanosan Mukodo ReszvenytarsasagInventors: Györgyi Kovanyine Lax, Gábor Nemeth, György Krasznay, Norbert Mesterhazy, Kálmán Nagy, Györgyi Vereczkeyné Donáth, Zsuzsanna Szent-Kirallyi
-
Publication number: 20110172210Abstract: Method for titrating clozapine in treatment of psychotic disorders in a human patient in need of treatment with clozapine including administering once-a-day controlled release clozapine to the human patient titrating to a therapeutic dose of clozapine within a period of less than one week, or administering controlled release clozapine to the patient at an initial dose of at least 37.5 mg and titrating to a therapeutic dose within a period of less than ten days.Type: ApplicationFiled: January 10, 2011Publication date: July 14, 2011Applicant: AZUR PHARMA LIMITEDInventors: Seamus MULLIGAN, Fintan KEEGAN
-
Publication number: 20110165259Abstract: [Problem to be Solved] The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. [Solution] A method for producing a composite organic compound powder for medical use is used which comprises: mixing a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxyvinyl polymer and fine-pulverizing the organic compound powder; and removing at least the salt and the polyol during or after fine-pulverizing.Type: ApplicationFiled: September 15, 2009Publication date: July 7, 2011Applicant: ACTIVUS PHARMA CO., LTD.Inventors: Takashi Hirokawa, Takahiro Tada, Jun Nihira
-
Publication number: 20110166128Abstract: The present invention provides prodrug compounds of diaryldiazepine drug compounds.Type: ApplicationFiled: December 23, 2010Publication date: July 7, 2011Applicant: Alkermes, Inc.Inventors: Julius F. Remenar, Laura Cook Blumberg
-
Patent number: 7973043Abstract: The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and/or using the method for smoking cessation or nicotine withdrawal.Type: GrantFiled: July 25, 2003Date of Patent: July 5, 2011Inventor: Peter Migaly
-
Patent number: 7973034Abstract: This disclosure relates to amides, aryl sulphonamides, aryl ureas, and ?,?-diketones derivatives useful as carboxylesterase esterase inhibitors. The disclosure is also directed to the use of these compounds as selective human intestinal carboxylesterase inhibitors and insect carboxylesterase inhibitors. The disclosure is also directed to pharmaceutical compositions and pesticide formulations containing these compounds, and to methods for treating or ameliorating the toxic effects following administration of drugs such as cancer therapy drugs, treating or ameliorating the effects of a drug overdose, and to the use of the compounds for increasing the effectiveness of insecticides and pesticides.Type: GrantFiled: February 15, 2008Date of Patent: July 5, 2011Assignee: St. Jude Children's Research HospitalInventors: Philip Michael Potter, Janice Louise Hyatt, Christopher Lee Morton, Paul P. Beroza, Komath V. Damoradan
-
Publication number: 20110158989Abstract: Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.Type: ApplicationFiled: March 4, 2011Publication date: June 30, 2011Applicant: Takeda Pharmaceutical Company LimitedInventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
-
Publication number: 20110160192Abstract: Compounds of formula (I): Z?-CO-A-B—NH-Z (I) wherein: Z is H or an amino protecting group; Z? is OH, a protected or activated hydroxyl group or Cl; A is an optionally substituted C5-6 arylene group; and B is an optionally substituted C5-6 arylene group.Type: ApplicationFiled: March 7, 2011Publication date: June 30, 2011Applicant: SPIROGEN LIMITEDInventors: Philip Wilson Howard, Geoffrey Wells
-
Publication number: 20110160191Abstract: The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R? represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R? represent a hydrogen atom.Type: ApplicationFiled: March 4, 2011Publication date: June 30, 2011Applicant: Ajinomoto Co., Inc.Inventors: Ryusuke HIRAMA, Seiji Niwa, Hideyuki Tanaka, Toshihiro Hatanaka, Yoko Masuzawa, Akiyo Yamazaki, Takao Ikenoue, Nobuo Kondo, Wataru Miyanaga, Masaru Takayanagi
-
Publication number: 20110152251Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.Type: ApplicationFiled: November 17, 2010Publication date: June 23, 2011Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
-
Patent number: 7960374Abstract: The present invention relates to compounds of the formula (I) wherein A, X and R1 to R9 are as described herein; to pharmaceutical compositions comprising the said compounds; to processes for their preparation; and to the use of the compounds as medicaments against 5-HT6 receptor-related disorders.Type: GrantFiled: October 30, 2007Date of Patent: June 14, 2011Assignee: Proximagen LimitedInventors: Peter Brandt, Erik Ringberg, Berts Wei, Rune Ringom, Kristin Hammer, Sofia Henriksson, Bengt Lindqvist
-
Publication number: 20110136790Abstract: The present invention relates to novel Tricyclic Heterocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Heterocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. R1 is formula (Ia), (Ib) or (Ic); R2 is alkvl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl. any of which can be optionally substituted with R11; M1 is —CH—. —C(halo)- or —N—; Y is —C(O)—, —S—. —S(O)—, —S(O)2—, —CH2— or —O—, such that Y is not —O— when an adjacent atom is N.Type: ApplicationFiled: July 21, 2009Publication date: June 9, 2011Inventors: Manuel De Lera Ruiz, MIchael Y Berlin, Junying Zheng, Robert G. Aslanian, Kenvin D. McCormick, Qingbel Zeng
-
Patent number: 7951798Abstract: The present invention relates to new crystalline forms I, II and III of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine hydrochloride, a process for the preparation thereof and pharmaceutical compositions containing the same. Said new polymorphic forms are useful as active ingredients for the treatment of psychotic conditions.Type: GrantFiled: April 22, 2004Date of Patent: May 31, 2011Assignee: Egis Hyogyszergyar Nyrt.Inventors: János Pethö, József Barkóczy, Péter Kótay Nagy, Gyula Simig, Zsuzsa Szent-Királlyi
-
Patent number: 7951799Abstract: The present invention provides a lactam compound, a sugar transport enhancement agent containing this compound as an active ingredient, an agent for the prevention and/or treatment of diabetes mellitus, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macrovascular disease, glucose tolerance anomaly, obesity and the like. In addition, the present invention also provides a preparation method for the novel lactam compound, and a preparation intermediate thereof.Type: GrantFiled: October 29, 2007Date of Patent: May 31, 2011Assignee: Ajinomoto Co., Inc.Inventors: Hideyuki Tanaka, Wataru Miyanaga, Masaru Takayanagi, Ryusuke Hirama, Yoko Kageyama, Tatsuya Ishikawa, Itsuya Tanabe, Yoriko Okamatsu
-
Publication number: 20110124633Abstract: In part, the present invention is directed to antibacterial compounds.Type: ApplicationFiled: July 27, 2010Publication date: May 26, 2011Inventors: Judd Berman, Peter Sampson, Heinz W. Pauls, Jailall Ramnauth, David Douglas Manning, Matthew David Surman, Dejian Xie, Helene Yvonne Decornez
-
Patent number: 7947678Abstract: Compounds of formula I: (where variables R2, R7, D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: GrantFiled: July 25, 2006Date of Patent: May 24, 2011Assignee: Merck Sharp & Dohme Corp.Inventor: Theresa M. Williams
-
Publication number: 20110117214Abstract: The present invention relates to new cyclohexyl urea modulators of D2 receptors and/or modulators of D3 receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 15, 2010Publication date: May 19, 2011Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Ronald C. Newbold, Chengzhi Zhang
-
Publication number: 20110118237Abstract: The present invention provides compounds of general formula (5a-d) and (9a-h) useful as potential antitumour agents against human cancer cell lines. The present invention also provides a process for the preparation of pyrrolo [2,1-c][1,4]benzodiazepine hybrids of general formula (5a-d) and (9a-h).Type: ApplicationFiled: October 31, 2008Publication date: May 19, 2011Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Kamal Ahmed, Jonnala Surendranadha Reddy, Dudekula Dastagiri, Earla Vijaya Bharathi
-
Patent number: 7943608Abstract: The invention relates to compounds of the formula (I), to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases in the development or course of which kinases are involved.Type: GrantFiled: November 28, 2006Date of Patent: May 17, 2011Assignee: Merck Patent GmbHInventors: Melanie Schultz, Lars Thore Burgdorf, Dirk Finsinger, Andree Blaukat, Hartmut Greiner, Christina Esdar
-
Publication number: 20110112069Abstract: The specification describes the use of selected purine derivatives for the treatment of hyperproliferative diseases.Type: ApplicationFiled: August 15, 2008Publication date: May 12, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Frank Himmelsbach, Michael Mark, Mohammad Tadayyon, Leo Thomas
-
Publication number: 20110105467Abstract: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: August 18, 2010Publication date: May 5, 2011Inventors: TIMOTHY L. RAMSEY, MARK D. BRENNAN
-
Publication number: 20110105468Abstract: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: August 18, 2010Publication date: May 5, 2011Inventors: Timothy L. Ramsey, Mark D. Brennan
-
Publication number: 20110105469Abstract: Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: November 3, 2010Publication date: May 5, 2011Applicant: Suregene, LLCInventors: Timothy L. Ramsey, Mark D. Brennan
-
Publication number: 20110105466Abstract: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: November 4, 2009Publication date: May 5, 2011Inventors: Timothy L. Ramsey, Mark D. Brennan
-
Patent number: 7932249Abstract: The present invention relates olanzapine pamoate dihydrate, pharmaceutical compositions thereof and use in treating certain mental disorders, such as schizophrenia.Type: GrantFiled: December 22, 2005Date of Patent: April 26, 2011Assignee: Eli Lilly and CompanyInventor: Julie Kay Bush
-
Publication number: 20110091544Abstract: Small tablets for use in procedural sedation, anxiolysis and analgesia comprising the combination sufentanil and triazolam administered via the oral transmucosal route and methods for using the same are provided.Type: ApplicationFiled: October 16, 2009Publication date: April 21, 2011Applicant: ACELRX PHARMACEUTICALS, INC.Inventor: Pamela Palmer
-
Patent number: 7928101Abstract: The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R? represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R? represent a hydrogen atom.Type: GrantFiled: May 1, 2006Date of Patent: April 19, 2011Assignee: Ajinomoto Co., Inc.Inventors: Ryusuke Hirama, Seiji Niwa, Hideyuki Tanaka, Toshihiro Hatanaka, Yoko Masuzawa, Akiyo Yamazaki, Takao Ikenoue, Nobuo Kondo, Wataru Miyanaga, Masaru Takayanagi
-
Publication number: 20110082111Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: ApplicationFiled: December 7, 2010Publication date: April 7, 2011Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Sheldon X. Cao, Victoria Feher, Takashi Ichikawa, Benjamin Jones, Stephen W. KALDOR, Andre A. KIRYANOV, Betty Lam, Yan Liu, Christopher McBride, Srinivasa Reddy Natala, Zhe Nie, Jeffrey A. Stafford
-
Publication number: 20110076276Abstract: The invention is related to compounds of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: June 26, 2008Publication date: March 31, 2011Applicants: Gilead Sciences, Inc., Korean Research Institute of Chemical TechnologyInventors: Hongyan Guo, Choung U. Kim, Ill Y. Lee, Michael L. Mitchell, Gerry Rhodes, Jong C. Son, Lianhong Xu